Community/Retail

The results of the INSPIRE trial demonstrated that 20.3% of individuals receiving risankizumab (Skyrizi) achieved clinical remission compared to 6.2% of individuals who received the placebo.

It is important for pharmacists to understand implications related to drug clearance to maximize therapeutics in patients with kidney disease.

Pharmacists on duty decline to dispense the medication to manage COVID-19, raising question about self-determination.

More and more data, both from real world analyses and clinical trials, are shedding light on the effective uses of cannabis, as well as the contraindications for its use in patients.

Even the terms themselves, “sex” and “gender,” are often misused and misunderstood by US society and medical professionals alike.

Imminent March, April expiration dates indicate changes are on the horizon for pharmacy services.

Therapy from Karuna Therapeutics demonstrates an 8.4-point reduction in Positive and Negative Syndrome Scale total score compared with the placebo at week 5.

Muneeb Shah, DO, dermatologist and partner at PC Dermatology PLLC, and Reid Maclellan, MD, founder of Cortina Health Inc, tackle misinformation and myths surrounding sun screen, skin cancer, and acne.

Michael D. Hogue, PharmD, FAPhA, FNAP, FFIP, discusses some of the ways that social determinants of health can impact patient health outcomes.

Although attention-deficit/hyperactivity disorder (ADHD) is not as common in adults, it can still be present and bothersome, however, adults with ADHD may have learned to hide it a bit better than children.

Prior to the pandemic, the seasonality of respiratory syncytial virus followed a pattern; now, this pattern of disease spread has changed significantly.

Specifically, non-opioids are often preferred for the management of subacute and chronic pain because of their safety profiles.

Pharmacy Times is covering the American Pharmacists Association (APhA) Annual Meeting & Exposition in Phoenix, Arizona from March 24 to 27, 2023.

Michael D. Hogue, PharmD, FAPhA, FNAP, FFIP, discusses current outlook on the occurrence of outbreaks of vaccine-preventable diseases in the country.

Specifically, 3 new drugs for sickle cell disease are providing options for patients who are not responding to hydroxyurea.

In addition to improving working conditions for current employees, burnout must be addressed in order to recruit and retain new employees and alleviate understaffing.

Phase 2B clinical trial results demonstrate that patients experienced improvement in total body and facial repigmentation.

Rezafungin (Rezzayo; Cidara Therapeutics Inc, Melinta Therapeutics LLC) is the first new treatment option approved for individuals with candidemia and invasive candidiasis in more than a decade.

As the risk of respiratory depression is elevated with opioid use, the risk of complications from COVID-19 is increased in patients with opioid use disorder.

Different guidelines have notable differences between equivalency dosing of proton pump inhibitors (PPI), resulting in confusion and a lack of confidence between medical professionals recommending one PPI over another.

Products include oral suspension for gout and tablets that prevent low carnitine levels in the blood.

The test did not reach the World Health Organization’s minimum performance requirement, which is 80% sensitivity for SARS-CoV-2, in the study population.

Expert Cmdr. Jennifer Lind, PharmD, MPH, MBA, discussed how her work in the CDC and the USPHS is a unique path for pharmacists interested in public health.

Children who died from fatal poisoning were often at home and in the presence of an adult.

In an additional post-hoc analysis, guselkumab demonstrated improvements at week 48, according to Janssen Pharmaceutical.

Kandy Dunnigan, AAS, CPhT-Adv, a drug diversion analyst at Novant Health, discusses her role in the pharmacy.

Services include adherence assessments, health screenings, medication reconciliation, vaccine administration.

Evinacumab-dgnb (Evkeeza; Regeneron Pharmaceuticals, Inc) is the first FDA-approved treatment indicated for children as young as 5 years of age to treat dangerously high levels of LDL-C.

The primary outcome of the study includes an IGA score of 0 or 1, which indicated clear or almost clear skin, respectively, with a reduction, from baseline to week 16.

John Beckner of National Community Pharmacists Association (NCPA) discusses how independent pharmacy plays a new role in primary care with Douglas Hoey, CEO of NCPA.